BIRC3 mutations are found in a smaller proportion of CLL patients (~4%) but they impact upon the non-canonical pathway due to the premature truncation of the BIRC3-encoded protein product, cIAP2. Here, BIRC3 is linked to B-cell chronic lymphocytic leukemia.